The concentration of calcitonin gene-related peptide (CGRP) in rat tissue extracts was determined by a specific and sensitive radio-immunoassay, and the distribution of its specific binding sites was assessed by radioligand binding studies. A high concentration of immunoreactive CGRP was found at all levels of the spinal cord, in the trigeminal nucleus, in trigeminal and dorsal root ganglia, in the thyroid gland, in blood vessels and in nerves. The highest density of specific binding sites was detected in the cerebellum, where the CGRP content was minimal. The dorsal portion of the spinal cord contained a high concentration of CGRP and its specific binding sites. Specific binding of 125I-CGRP was also demonstrated in a number of other areas of the brain and in certain peripheral tissues. Among the other tissues examined, the spleen, adrenal gland, penis, lungs, bladder, heart and blood vessels all contained a large number of CGRP binding sites, whereas only a negligible number of sites were found in ganglia, nerves, muscle, kidney and liver. The distribution of CGRP and its specific binding sites demonstrated here suggests that CGRP is a neuropeptide with multiple physiological roles.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.